




ISSN 2010-6882

DERMATOVENEROLOGIYA VA ESTETIK TIBBIYOT

Ilmiy-amaliy jurnal



№ 1/2014 (21)

ДЕРМАТОВЕНЕРОЛОГИЯ И ЭСТЕТИЧЕСКАЯ МЕДИЦИНА

Научно-практический журнал

REPUBLICAN SPECIALIZED SCIENTIFIC-PRACTICAL MEDICAL CENTRE OF
DERMATOLOGY AND VENEREOLOGY OF THE MINISTRY OF HEALTH OF
THE REPUBLIC OF UZBEKISTAN

ASSOCIATION OF DERMATOVENEROLOGISTS OF UZBEKISTAN

DERMATOVENEROLOGIYA VA ESTETIK TIBBIYOT

ILMIY- AMALIY JURNAL

DERMATOVENEROLOGY AND AESTHETIC MEDICINE

SCHOLARLY JOURNAL

Founded in 2008

№ 1/2014 (21)

TASHKENT - 2014

PERSPECTIVES FOR THE USE OF VIUSID IN DERMATOLOGY

RACHMATOV A.B., MIRHAMIDOVA N.V.

***Republican Specialized Scientific and Practical Medical Centre of Dermatology and Venereology
of the Ministry of Health of the Republic of Uzbekistan***

In recent years, the number of patients suffering from chronic skin diseases (psoriasis, lupus erythematosus, lupus erythematosus, etc.), the pathogenesis of which is clearly autoimmune, has been increasing. In addition, in many dermatoses the role of viral infection cannot be completely ruled out, and this should be taken into account in the development of etiopathogenetic therapy for any dermatosis.

Today, advanced science offers a wide range of natural substances for this purpose, in particular, the biologically active preparation "Viusid", which consists of safe natural compounds. For this reason, the use of Viusid does not lead to the development of any side effects, which is inevitable to some extent with virtually all pharmaceutical agents.

Psoriasis is a disease characterized by increased proliferation of keratinocytes, which may be due to the effects of retroviruses along with the development of immunosuppression. It is possible that the virus-like particles associated with psoriasis are subcellular fragments enclosed in the plasma membrane but without genomic viral RNA.

The above etiopathogenetic mechanisms of psoriasis make it possible to use drugs that are able to affect both the immune system and exert a certain antiviral effect. Such a drug is "Viusid", which was created to increase immune protection in all processes associated with immunodeficiency and may contribute to a lower viral background in psoriasis patients.

The aim of the present study was to investigate the therapeutic efficacy of Viusid in psoriasis patients.

Sixty-four psoriasis patients (men-38, women-26) aged 20 to 45 years were followed. Patients with the usual, large-muscle form of psoriasis were selected for the study and divided into two groups comparable in sex, age, and disease duration. The first group (control) - 32 patients - received standard treatment; the second group (main group) - 32 patients - were additionally administered the drug "Viusid" 5 g (one packet) twice a day for 20-30 days. The therapeutic efficacy was evaluated using the PASI index.

The inclusion of the drug "Viusid" in the complex therapy of psoriasis patients allows to increase the therapeutic efficacy from 64,1 % to 89,3 %, which is an undeniable proof of the expediency of the use of the mentioned agent. The use of Viusid resulted in the normalization of immune and cytokine status indicators, especially cytokine TNF- α . In addition, patients with psoriasis who received Viusid showed positive dynamics in biochemical parameters characterizing the so-called metabolic syndrome (transaminase activity, high-density lipoprotein, medium-molecular peptide, etc.).

Thus, the studies conducted allowed to substantiate the expediency of using the preparation "Viusid" in the treatment of psoriasis patients. The absence of any side effects, ease of use and high patient compliance is a serious argument for the widespread introduction of this agent in practical dermatology.